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Solid dispersion (SD) is one of the most common strategies for improving the dissolution behavior of Biopharmaceutics Classification System (BCS) Class II 
compounds. In this study, we use a supercritical CO2 (sc-CO2) process for preparing SD, namely Particles from Gas Saturated Solutions (PGSS). The 
interest of this process was evaluated by testing several Gelucire® based formulations of fenofibrate in vitro and in vivo. 
Particles were produced using a PGSS apparatus (Fig. 1) from Separex® (Champigneulles, France). It consisted 
of a saturation vessel (50 mL) equipped with a mechanic stirrer and an expansion chamber (18 L) connected to 
the saturation vessel through a manual valve and an expansion nozzle. The API was melted in the saturation 
compartment with Gelucire® 50/13 (Gattefossé, Saint-Priest, France). The melted mixture was put into contact 
with supercritical carbon dioxide and mixed during a predetermined period and speed at the established pre-
expansion pressure and temperature conditions. The expansion valve was then opened and the gas saturated 
solution was expanded through a nozzle of a predetermined diameter. 
The PGSS formulation (fenofibrate + Gelucire ® 50/13) and the PGSS process were optimized by means of a 
design of experiments [1]. This optimal PGSS formulation was compared to a SD produced by melt mixing at the 
same concentration (220 mg of fenofibrate per gram of Gelucire®). This SD was obtained by melting both 
products together and micronizing this mixture to obtain a particle size comparable to the PGSS product. 
Fig. 1 : Photo of the PGSS equipment 
In vitro dissolution experiments 
The in vitro dissolution test used was a biphasic dissolution test (Fig. 2). This biphasic system consisted of 
a aqueous phase (300 mL HCl 0.1 M) and an organic phase (200 mL octanol) in a USP II apparatus 
combined with an USP IV apparatus. Two dissolution profiles were determined (aqueous phase and 
organic phase) after quantification analysis of dissolution media samples by HPLC (n = 6). 
Fig. 2 : Schematic representation of the biphasic dissolution system 
In vivo experiments 
The in vivo study was performed on Pietrain crossed Landrace pigs (n = 4) after an overnight fasting period of 12 h. Due to financial 
restrictions, this study was carried out according to a balance incomplete block design. The administered dose of fenofibrate was 2 
mg/kg of body weight. After administration, blood samples (8 mL) were collected at time zero (pre-dosing), 1 h, 2 h, 3 h, 3.5 h, 4 h, 
4.5 h, 5 h, 5.5 h, 6 h, 6.5 h, 8 h, 9 h, 10 h, 11 h, 12 h, 24 h and 36 h post-dosing. Fenofibric acid plasma concentrations were 
determined by liquid chromatography coupled to a tandem mass spectrometry detection system (LC-MS/MS, API 4000, AB Sciex, 
Toronto,Canada). The pharmacokinetic parameters Cmax, Tmax and AUC0-t of fenofibric acid were calculated. 
In vitro study 
In vivo study 
Regarding the in vitro results, the PGSS and the SD formulations had a very similar dissolution 
profile in the organic phase (f2 = 61). However, the results were different in the aqueous phase. 
For the SD formulation, the maximal concentration (Cmax) was reached after 10h and decreased 
shortly afterwards. The average Cmax was about 155 µg/mL and the calculated Maximum 
Supersaturation Ration (SRM) was 1.89 ± 0.09. In comparison, for the PGSS formulation, Cmax 
was reached earlier (7h) and was maintained over a longer period (approximately 3h). This 
average Cmax was about 190 µg/mL and thus, the calculated SRM was also higher (SR
M = 2.28 
± 0.14). Given these results, the improvement of the oral bioavailability of fenofibrate should be 
more pronounced with the PGSS formulation as a result both of supersaturation being 
maintained for a longer period and the higher SRM value attained.  
The mean measured plasmatic profiles of fenofibric acid after administration of the PGSS 
product and the micronized SD are shown in Fig.4. From these profiles, the 
pharmacokinetic parameters Cmax, Tmax and AUC0-t were calculated (Table 1). The PGSS 
formulation showed a higher value of Cmax and AUC0-t compared to the SD formulation. 
The Tmax value was also shorter for the PGSS formulation. Regarding these results, the 
bioavailability of fenofibrate seems to be better after the administration of the PGSS 
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Fig. 3 : Dissolution profiles  (n = 6) obtained in the aqueous phase of the biphasic 
dissolution test for the PGSS product (in orange) and the micronized solid dispersion 
(in green) at the same drug loading level (220 mg/g). 
Fig. 4 : The mean measured (n = 4) plasmatic profiles of  fenofibric acid after 
administration of the PGSS product (in orange) and the micronized solid dispersion (in 
green) at the same drug loading level (220 mg/g). 
Cmax (ng/mL) AUC Tmax (min) 
SD 220 1536 ± 15 19216 ± 27 450 
PGSS 220 2016 ± 12 19858 ± 27 190 
Table. 1 : The calculated pharmacokinetic parameters of fenofibric acid after administration of the PGSS 
product (PGSS 220) and the micronized solid dispersion (SD 220) at the same drug loading level (220 mg/g). 
The variability was expressed by the Standard Error of Mean (SEM). The optimized PGSS formulation and the classical SD were tested in vitro 
using a biphasic dissolution test and the observations in the aqueous 
phase seem to be well correlated with the results obtained in vivo. 
Therefore, the PGSS process is interesting compared to a classical 
method such as melt mixing for the production of fenofibrate lipid based 
SD. This could be probably explained by the high porosity of the 
produced powder and the reduced size of fenofibrate crystals generated 
by the process.  
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